Nordic Group BV

• Nordic Pharma, a subsidiary of Nordic Group B.V., has partnered with Harrow to launch an authorized generic version of Maxitrol ophthalmic suspension for treating bacterial eye infections. • The new generic alternative enters a market where Maxitrol and its generic equivalents generated annual sales of $20.8 million in the U.S. as of January 2025, according to IQVIA data. • This product expansion strengthens Nordic Pharma's generic portfolio and aims to provide patients with a more affordable prescription option for treating ocular bacterial infections.

• Nordic Pharma has received CE Mark approval in the European Union for Lacrifill, a cross-linked hyaluronic acid gel that temporarily blocks tear drainage by occluding the canalicular system. • The innovative treatment offers a single in-office procedure with effects lasting up to 6 months, addressing a condition that affects approximately 30% of the European population. • Lacrifill, which previously received U.S. approval in June 2024, demonstrated promising results in a pilot study where 83% of participants experienced no pain and 63% reported improved eye comfort after treatment.